Related Experiment Video
Updated: Jun 23, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Seroprotection after a Standard Three-Dose Hepatitis B Vaccination Series in Immune-Mediated Rheumatic Diseases: A
Yeliz Çiçek1, Feride Merve Arslan2, Gülay Alp3
1Epidemiology Doctorate Program, Graduate School of Health Sciences, Istanbul Medipol University, Istanbul, Türkiye.
Objective:
This study aimed to evaluate seroprotection rates after a standard three-dose hepatitis B vaccination series in adults with immune-mediated rheumatic diseases (IMRDs) and to identify clinical and treatment-related factors associated with vaccine response in routine clinical practice.
Materials And Methods:
This retrospective observational study was conducted between January 2022 and August 2024. Adults with rheumatologist-confirmed IMRDs who were susceptible to hepatitis B virus (HBV) at baseline and who underwent quantitative hepatitis B surface antibody (anti-HBs) testing 4-8 weeks after receipt of the third vaccine dose were included.
Results:
Of 260 eligible patients, 161 completed the standard three-dose hepatitis B vaccination series, and post-vaccination anti-HBs results were available for 152 patients included in the final analysis. Seroprotection was achieved in 110 (72.4%) patients. In multivariable logistic regression analysis, longer disease duration and systemic corticosteroid exposure were independently associated with lower odds of achieving seroprotection. Age, sex, smoking status, body mass index, and comorbidity burden were not independently associated with vaccine response.
Conclusion:
In adults with IMRDs, approximately three-quarters achieved seroprotection after standard hepatitis B vaccination. Longer disease duration and systemic corticosteroid exposure were independently associated with reduced serologic response. These findings highlight the importance of timely vaccination and consideration of cumulative immunosuppressive burden in routine clinical practice.
Graphic Abstract:
Graphic Abstract.
Related Concept Videos
Respiratory Syncytial Virus Disease
Rheumatic Heart Disease III: Medical Management
Hepatitis
Viral Hepatitis I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Hypersensitivity Reactions: Immune-Complex Reactions